293 related articles for article (PubMed ID: 30854892)
1. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
Burgos RM; Rodvold KA
Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
[TBL] [Abstract][Full Text] [Related]
2. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Kaye KS; Rice LB; Dane AL; Stus V; Sagan O; Fedosiuk E; Das AF; Skarinsky D; Eckburg PB; Ellis-Grosse EJ
Clin Infect Dis; 2019 Nov; 69(12):2045-2056. PubMed ID: 30861061
[TBL] [Abstract][Full Text] [Related]
3. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
Shorr AF; Pogue JM; Mohr JF
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
[TBL] [Abstract][Full Text] [Related]
4. Oral and intravenous fosfomycin in complicated urinary tract infections.
López-Montesinos I; Horcajada JP
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
[TBL] [Abstract][Full Text] [Related]
5. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
6. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
7. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
[TBL] [Abstract][Full Text] [Related]
8. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
Reffert JL; Smith WJ
Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
[TBL] [Abstract][Full Text] [Related]
9. Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.
Pourbaix A; Guérin F; Burdet C; Massias L; Chau F; Cattoir V; Fantin B
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160291
[TBL] [Abstract][Full Text] [Related]
10. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
[TBL] [Abstract][Full Text] [Related]
11. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
12. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
Trinh TD; Smith JR; Rybak MJ
Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
[TBL] [Abstract][Full Text] [Related]
13. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
Rudenko N; Dorofeyev A
Arzneimittelforschung; 2005; 55(7):420-7. PubMed ID: 16080282
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
Diep JK; Sharma R; Ellis-Grosse EJ; Abboud CS; Rao GG
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203494
[TBL] [Abstract][Full Text] [Related]
15. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
Peters HJ; Eicher R
MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
[TBL] [Abstract][Full Text] [Related]
17. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.
Cottell JL; Webber MA
J Med Microbiol; 2019 Feb; 68(2):161-168. PubMed ID: 30543320
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women.
Matsumoto T; Muratani T; Nakahama C; Tomono K
J Infect Chemother; 2011 Feb; 17(1):80-6. PubMed ID: 20694571
[TBL] [Abstract][Full Text] [Related]
19. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
Candel FJ; Matesanz David M; Barberán J
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
[TBL] [Abstract][Full Text] [Related]
20. Fosfomycin: an old--new antibiotic.
Raz R
Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
